Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting

Chief Scientific Officer Erin Duffy to Present in Meet-the-Experts Session: Antimicrobial Discovery Approaches

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that the company and investigators will be making five presentations at ASM Microbe 2016, which takes place in Boston, MA on June 16-20. Specifically, Melinta will present four posters on Baxdela™ (delafloxacin), an investigational anionic quinolone being assessed for the treatment of patients with serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and complicated urinary tract infections (cUTI).